MSN Laboratories Private Limited — Montelukast Exporter Profile
Indian Pharmaceutical Exporter · #10 for Montelukast · $3.2M export value · DGFT Verified
MSN Laboratories Private Limited is the #10 Indian exporter of Montelukast with $3.2M in export value and 295 verified shipments. MSN Laboratories Private Limited holds a 1.9% market share in Montelukast exports across 18 countries. The company exports 32 pharmaceutical products worth $252.1M across 15 therapeutic categories.
MSN Laboratories Private Limited — Montelukast Export Profile: Buyers & Destinations
Where Does MSN Laboratories Private Limited Export Montelukast?
| Country | Value | Shipments | Share |
|---|---|---|---|
| JAMAICA | $1.1M | 58 | 42.1% |
| MAURITIUS | $445.7K | 27 | 17.3% |
| ZAMBIA | $157.1K | 45 | 6.1% |
| FRANCE | $134.0K | 19 | 5.2% |
| TANZANIA | $130.8K | 29 | 5.1% |
| UGANDA | $93.3K | 17 | 3.6% |
| COLOMBIA | $91.0K | 13 | 3.5% |
| ZIMBABWE | $84.0K | 12 | 3.3% |
| KENYA | $67.1K | 8 | 2.6% |
| AFGHANISTAN | $64.6K | 6 | 2.5% |
MSN Laboratories Private Limited exports Montelukast to 21 countries. The largest destination is JAMAICA accounting for 42.1% of MSN Laboratories Private Limited's Montelukast shipments, followed by MAURITIUS (17.3%) and ZAMBIA (6.1%). These destinations reflect MSN Laboratories Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Montelukast from MSN Laboratories Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER OF | ZIMBABWE | $672.5K | 82 |
| TO THE ORDER OF., | JAMAICA | $243.6K | 16 |
| SCOTT HEALTH LTD | MAURITIUS | $240.2K | 11 |
| LASCO DISTRIBUTORS LTD | JAMAICA | $214.3K | 15 |
| LASCO DISTRIBUTORS LTD, | JAMAICA | $150.0K | 3 |
| LASCO DISTRIBUTORS LTD , | JAMAICA | $133.0K | 8 |
| LASCO DISTRIBUTORS LIMITED | JAMAICA | $117.6K | 7 |
| MEGA WECARE TANZANIA LIMITED | TANZANIA | $81.2K | 11 |
| SCOTT HEALTH LIMITED | MAURITIUS | $63.6K | 3 |
| KARIBU PHARMACEUTICALS LTD | ZAMBIA | $63.0K | 14 |
MSN Laboratories Private Limited supplies Montelukast to 47 buyers globally. The largest buyer is TO THE ORDER OF (ZIMBABWE), followed by TO THE ORDER OF., (JAMAICA) and SCOTT HEALTH LTD (MAURITIUS). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Montelukast Export Value and How Much Does MSN Laboratories Private Limited Contribute?
India exported $73.6M worth of Montelukast through 6,431 shipments from 510 suppliers to 138 countries, serving 1,324 buyers globally. MSN Laboratories Private Limited contributes $3.2M to this total, accounting for 1.9% of India's Montelukast exports. MSN Laboratories Private Limited ships Montelukast to 21 countries through 47 buyers.
What Is the Average Shipment Value for MSN Laboratories Private Limited's Montelukast Exports?
MSN Laboratories Private Limited's average Montelukast shipment value is $10.7K per consignment, based on 295 shipments totaling $3.2M. The largest destination is JAMAICA (42.1% of MSN Laboratories Private Limited's Montelukast exports).
How Does MSN Laboratories Private Limited Compare to Other Indian Montelukast Exporters?
MSN Laboratories Private Limited ranks #10 among 510 Indian Montelukast exporters with a 1.9% market share. The top 3 exporters are UNICHEM LABORATORIES LIMITED ($13.1M), MACLEODS PHARMACEUTICALS LTD ($11.6M), DR.REDDY'S LABORATORIES LTD ($9.4M). MSN Laboratories Private Limited processed 295 shipments to 18 destination countries.
What Montelukast Formulations Does MSN Laboratories Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| BREATHEZY L (MONTELUKAST+LEVOCITIRIZ 10+5) 3X10 | $150.0K | 3 |
| MSN PHARMA- LEUTRIEN 10 (MONTELUKAST 10M | $86.6K | 3 |
| MSN LABS, BREATHEZY 10 (MONTELUKAST 10MG | $69.6K | 4 |
| Breathezy 10 Montelukast 10mg 3x10 BATCH NO BRF03077C | $67.3K | 4 |
| BREATHEZY 10 (MONTELUKAST 10MG) 3X10 | $64.8K | 5 |
| BREATHEZY 10 (MONTELUKAST 10MG) 3X10NOS | $53.9K | 2 |
| BREATHEZY L (MONTELUKAST+LEVOCITIRIZ 10+ | $52.1K | 3 |
| MSN PHARMACEUTICALS BREATHEZY L MONTELUKAST LEVOCITIRIZ 10 5 3X10 | $50.0K | 2 |
| MSN LABS, BREATHEZY L (MONTELUKAST+ LEVO | $50.0K | 1 |
| BREATHEZY 10 MONTELUKAST 10MG 3X10 | $50.0K | 1 |
MSN Laboratories Private Limited exports 213 distinct Montelukast formulations including tablets, capsules, syrups, and combination drugs. The top formulation is BREATHEZY L (MONTELUKAST+LEVOCITIRIZ 10+5) 3X10 with 3 shipments worth $150.0K.
How Does MSN Laboratories Private Limited Compare to Nearest Montelukast Exporters?
Exporters ranked immediately above and below #10 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | CIPLA LIMITED | $4.6M | 92 | 5 | $50.0K |
| 8 | INTAS PHARMACEUTICALS LIMITED | $3.8M | 400 | 10 | $9.4K |
| 10 | MSN LABORATORIES PRIVATE LIMITED ★ | $3.2M | 295 | 18 | $10.7K |
| 11 | TORRENT PHARMACEUTICALS LIMITED | $3.1M | 77 | 13 | $39.7K |
| 9 | INDOCO REMEDIES LIMITED | $3.0M | 61 | 2 | $50.0K |
MSN Laboratories Private Limited ranks #10 among 510 Indian Montelukast exporters. Average shipment value of $10.7K compared to the market average of $144.3K. The closest competitors by value are CIPLA LIMITED and INTAS PHARMACEUTICALS LIMITED.
Which Indian Ports Ship Montelukast Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 537 | 8.4% |
| NHAVA SHEVA SEA (INNSA1) | 528 | 8.2% |
| SAHAR AIR | 479 | 7.4% |
| SAHAR AIR CARGO ACC (INBOM4) | 466 | 7.2% |
| DELHI AIR | 451 | 7.0% |
| JNPT/ NHAVA SHEVA SEA | 286 | 4.4% |
| JNPT | 224 | 3.5% |
| MUNDRA SEA | 214 | 3.3% |
Geopolitical & Trade Policy Impact on MSN Laboratories Private Limited's Montelukast Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like MSN Laboratories. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major shipping lines to alter routes. This has resulted in extended transit times by 10–20 days and a 40–50% increase in freight rates on key India–Europe routes, impacting the timely delivery of pharmaceutical products. (livemint.com)
Conversely, the ongoing US-China trade tensions have prompted the United States to diversify its pharmaceutical supply chain, potentially benefiting Indian exporters. However, the imposition of tariffs on Indian pharmaceutical products poses a risk to export volumes, as higher tariffs can lead to increased costs and reduced competitiveness in the US market. (orfonline.org)
In the European Union, compliance with the Falsified Medicines Directive (FMD) requires stringent serialization and traceability measures. For companies like MSN Laboratories, adhering to these regulations is crucial to maintain market access and ensure the integrity of their supply chain.
MSN Laboratories Private Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA), World Health Organization (WHO), and European Union Good Manufacturing Practice (EU GMP) guidelines set rigorous quality benchmarks. Any lapses can lead to import bans, product recalls, and reputational damage.
MSN Laboratories' recent legal challenges, such as the patent litigation with Exelixis, Inc., highlight the importance of robust regulatory and intellectual property strategies. Ensuring compliance with evolving quality requirements and proactively addressing regulatory challenges are essential for sustaining export growth and market credibility.
About MSN Laboratories Private Limited
MSN Laboratories Private Limited exports 32 products worth $252.1M. Beyond Montelukast, top products include Atorvastatin, Rosuvastatin, Ras, Oseltamivir, Calcium. View the complete MSN Laboratories Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Montelukast — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Montelukast shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: MSN Laboratories Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 295 individual customs records matching MSN Laboratories Private Limited exporting Montelukast, covering 213 formulations to 21 countries via 47 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 138+ countries, 1,324+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Montelukast Export Data from MSN Laboratories Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for MSN Laboratories Private Limited's Montelukast exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
MSN Laboratories Private Limited
Full Company Profile →
32 products · $252.1M total trade · 15 categories
Montelukast Stats
Company Overview
Top Products by MSN Laboratories Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for MSN Laboratories Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Montelukast. For current shipment-level data, contact TransData Nexus.